HemoClear™: A Thin Fluid Film Device (TFFD™) for evacuating Blood and eliminating fogging on Surgical and Implant Lenses

S.A. Sinha, A.J. Acharya, N. Herbots, E.J. Culbertson, C.F. Watson, M. Matiski, A.J. Orr, R.B. Bennett-Kennett, A.M. Murphy, B.W. Hughes, A.S. Benitez, T.T. Kutz, D.A. Sell, E.R. Morgan, A.L. Brimhall, R.J. Culbertson
Arizona State University/SiO2 NanoTech, LLC., US

Keywords: fogging, optic, optical, lenses, anti-fog, surgery, medical device accessory, emulsion, hydro-affinity, hydrophilic, hydrophobic, SiO2, scope, blood protein, fibrinogen, infection prevention, scarring, closed body cavity surgery, condensation, bodily fluids

Summary:

During closed body cavity surgery, the view through the lens of surgical scopes is often obstructed by the condensation of water (fog) and blood on the lens surface; this forces surgeons to repeatedly remove the scope and wipe the lens. Consequently, surgery duration increases (by up to 40%), as does risk of infection and scarring due to removal and reinsertion of the scope, defeating the purpose of closed body cavity surgery. HemoClear™, a Thin Fluid Film Device (TFFD™), is a layered emulsion combining VitreOx™ and fibrinogen. VitreOx™ is an anti-fog TFFD™, free of optical aberration, optically transparent, and super-hydrophilic for up to 48 hours after application on a lens (although it has been formulated to last much longer for non-surgical applications). Our research has demonstrated that fibrinogen can effectively evacuate blood from a lens without interfering with anti-fog activity. Ongoing research seeks to establish the fibrinogen concentration range where blood is effectively evacuated when fibrinogen is combined with VitreOx™. The mixing and layering procedure of HemoClear™ components is tested with simulated in vivo clinical trials to identify the smallest effective dose of fibrinogen that allows for the evacuation of blood while still inhibiting fogging.